Table 1

Overall observed 3-, 5- and 10-year survival rates of TCs for both genders in relation to the 4 age cohorts (<20 years, 20–44 years, 45–69 years and >69 years of age) and the 4 histological types (papillary, follicular, medullary and anaplastic carcinomas); n = 310 cases; period 1990–1999.

1990–1994


Papillary carcinomas

Follicular carcinomas

Medullary carcinomas

Anaplastic carcinomas


3 y

5 y

10 y

3 y

5 y

10 y

3 y

5 y

10 y

3 y

5 y

10 y


<20 years

(0/0)

(0/0)

(0/0)

(0/0)

(0/0)

(0/0)

(0/0)

(0/0)

(0/0)

(0/0)

(0/0)

(0/0)

20–44 y.

100% (42/42)

100% (42/42)

97.6%* (41/42)

100% (9/9)

100% (9/9)

88.9%* (8/9)

(0/0)

(0/0)

(0/0)

(0/0)

(0/0)

(0/0)

45–69 y.

91.8%* (45/49)

89.8%* (44/49)

87.8%* (43/49)

90.9%* (10/11)

90.9%* (10/11)

81.8%* (9/11)

66.7%* (2/3)

66.7%* (2/3)

66.7%* (2/3)

(0/0)

(0/0)

(0/0)

>69 years

66.7%* (2/3)

33.3%* (1/3)

0% (0/3)

57.1%* (4/7)

42.9%* (3/7)

42.9%* (3/7)

100% (1/1)

100% 1/1)

100% (1/1)

0% (0/1)

0% (0/1)

0% (0/1)


1995–1999


Papillary carcinomas

Follicular carcinomas

medullary carcinomas

Anaplastic carcinomas


3 y

5 y

10 y**

3 y

5 y

10 y**

3 y

5 y

10 y**

3 y

5 y

10 y**


<20 years

100% (3/3)

100% (3/3)

-

(0/0)

(0/0)

-

(0/0)

(0/0)

-

(0/0)

(0/0)

-

20–44 y.

100% (65/65)

100% (65/65)

-

100% (7/7)

100% (7/7)

-

100% (3/3)

100% (3/3)

-

(0/0)

(0/0)

-

45–69 y.

98.7%* (76/77)

98.7%* (76/77)

-

100% (9/9)

100% (9/9)

-

100% (4/4)

100% (4/4)

-

0% (0/2)

0% (0/2)

-

>69 years

88.9%* (8/9)

77.8%* (7/9)

-

50%* (1/2)

50%* (1/2)

-

(0/0)

(0/0)

-

0% (0/3)

0% (0/3)

-


1990–1999


Papillary carcinomas

Follicular carcinomas

medullary carcinomas

Anaplastic carcinomas


3 y

5 y

10 y**

3 y

5 y

10 y**

3 y

5 y

10 y**

3 y

5 y

10 y**


<20 years

100% (3/3)

100% (3/3)

-

(0/0)

(0/0)

-

(0/0)

(0/0)

-

(0/0)

(0/0)

-

20–44 y.

100% (107/107)

100% (107/107)

-

100% (16/16)

100% (16/16)

-

100% (3/3)

100% (3/3)

-

(0/0)

(0/0)

-

45–69 y.

96.0%* (121/126)

95.2%* (120/126)

-

95.0%* (19/20)

95%* (19/20)

-

85.7%* (6/7)

85.7%* (6/7)

-

0% (0/2)

0% (0/2)

-

>69 years

83.3%* (10/12)

66.7%* (8/12)

-

55.6%* (5/9)

44.4%* (4/9)

-

100% (1/1)

100% (1/1)

-

0% (0/4)

0% (0/4)

-


* sample size too small for calculating the 95% confidence interval

** data not yet available

Scheiden et al. BMC Cancer 2006 6:102   doi:10.1186/1471-2407-6-102

Open Data